Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement
International Journal of Molecular Sciences · 26.01.2024 · 25 (3) · 1557
DOI: 10.3390/ijms25031557 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.01.2024. Verfasst von Emily Gill und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Endocrinology Group, Learning & Research Building, Southmead Hospital, Translational Health Sciences, Bristol Medical School, Bristol BS10 5NB…. Hauptthemen laut MEDLINE: Quality of Life, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bristol.
Abstract (Originalsprache)
Bladder cancer is the tenth most common cancer and is a significant burden on health care services worldwide, as it is one of the most costly cancers to treat per patient. This expense is due to the extensive treatment and follow-ups that occur with costly and invasive procedures. Improvement in both treatment options and the quality of life these interventions offer has not progressed at the rates of other cancers, and new alternatives are desperately needed to ease the burden. A more modern approach needs to be taken, with urinary biomarkers being a positive step in making treatments more patient-friendly, but there is still a long way to go to make these widely available and of a comparable standard to the current treatment options. New targets to hit the major signalling pathways that are upregulated in bladder cancer, such as the PI3K/AkT/mTOR pathway, are urgently needed, with only one drug approved so far, Erdafitinib. Immune checkpoint inhibitors also hold promise, with both PD-1 and CDLA-4 antibody therapies approved for use. They effectively block ligand/receptor binding to block the immune checkpoint used by tumour cells. Other avenues must be explored, including drug repurposing and novel biomarkers, which have revolutionised this area in other cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Endocrinology Group, Learning & Research Building, Southmead Hospital, Translational Health Sciences, Bristol Medical School, Bristol BS10 5NB, UK.
ORCID-Profile: Emily Gill, Claire M Perks
Förderung
- University of Bristol
Zitieren
APA
Gill, E., & Perks, C. M. (2024). Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement. International Journal of Molecular Sciences, 25(3), 1557. https://doi.org/10.3390/ijms25031557
Vancouver
Gill E, Perks CM. Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement. International Journal of Molecular Sciences. 2024;25(3):1557. doi:10.3390/ijms25031557
BibTeX
@article{Gill2024,
author = {Gill, Emily and Perks, Claire M},
title = {Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {3},
pages = {1557},
doi = {10.3390/ijms25031557}
}
EUVIMED